Tiziana Life Sciences is trading at $1.08, up 2.9%, with no clearly linked company catalyst identified for October 16. - Shares compare with the October 15 close of $1.05. - The latest company updates located were dated September 28–30, including the first participants dosed in its ALS BANYAN trial; that earlier news does not establish a cause for the pre-market move. - Major index moves supplied were modest, and premarket volume was not provided in the price context.